Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in ...
MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH. Part 1 of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results